Cjc-1295 No Dac Lab Tested

Defining CJC-1295 No DAC Laboratory Verification

A CJC-1295 No DAC lab tested reference material is a synthetic 29-amino acid Growth Hormone-Releasing Hormone (GHRH) analog—technically designated as Modified GRF 1-29—that has undergone rigorous analytical validation. Laboratory testing confirms structural identity via Mass Spectrometry, quantitative purity exceeding 99% via High-Performance Liquid Chromatography (HPLC), and absolute freedom from microbial contamination via limulus amebocyte lysate (LAL) endotoxin testing.

When purchasing compounds for controlled laboratory experiments, selecting verified material is critical to preventing uncharacterized side reactions or erratic receptor activation profiles. Investigators sourcing the CJC-1295 No DAC reference peptide rely on lot-specific documentation to validate molar concentration, peptide content, and structural purity prior to initiating in vitro or animal models.

Molecular Structure and GHRH Receptor Affinity

CJC-1295 No DAC is a tetrasubstituted peptide derivative of natural GHRH(1-29). The native 29-amino acid fragment of human GHRH is susceptible to rapid enzymatic cleavage in physiological environments, particularly by the enzyme dipeptidyl peptidase IV (DPP-IV). To enhance enzymatic resistance while maintaining affinity for the GHRH receptor, amino acid substitutions are introduced at positions 2, 8, 15, and 27 (typically D-Ala2, Gln8, Ala15, and Leu27).

These structural modifications preserve high binding affinity for the anterior pituitary GHRH receptors while dramatically extending the peptide's half-life compared to endogenous GHRH(1-29). In baseline biochemical assays, this molecular conformation permits sustained receptor binding without altering the secondary signaling pathways that stimulate adenylate cyclase and intracellular cAMP accumulation.

Preclinical Research Mechanisms: GH and IGF-1 Pulsatility

In published literature, CJC-1295 No DAC is studied as a long-acting growth-hormone-releasing hormone that sustains GH and downstream IGF-1 levels for tissue repair research. Preclinical animal models demonstrate that binding of this GHRH analog to somatotroph receptors stimulates the transcription and release of endogenous growth hormone in a physiological, pulsatile fashion.

Unlike continuous exposure compounds that risk receptor downregulation or somatotroph desensitization, CJC-1295 No DAC preserves natural pulsatile release mechanisms. Elevated serum growth hormone subsequently signals hepatic tissues to upregulate Insulin-like Growth Factor 1 (IGF-1) synthesis. In vitro and rodent studies utilize this axis to examine cellular proliferation, collagen cross-linking, myoblast differentiation, and extracellular matrix remodeling during wound recovery assays. Researchers interested in exploring broader hormonal pathways can review documentation across our complete catalog of research peptides.

Structural Comparison: CJC-1295 No DAC vs. Related GHRH Analogs

Understanding the differences among growth hormone secretagogues is critical for designing controlled experimental paradigms. CJC-1295 No DAC (Mod GRF 1-29) lacks the Drug Affinity Complex (DAC) reactive chemical motif. The inclusion of DAC creates a covalent bond with endogenous plasma albumin, extending biological half-life from tens of minutes to several days. Researchers evaluating kinetic profiles often consult the dedicated breakdown on CJC-1295 with DAC structural comparison to determine which half-life profile suits their specific perfusion or sampling schedule.

When compared to early-generation GHRH fragments like Sermorelin GHRH fragment, CJC-1295 No DAC exhibits markedly superior plasma stability due to its four amino acid substitutions against DPP-IV degradation. Furthermore, in dual-receptor signaling models, scientists frequently combine GHRH secretagogues with ghrelin mimetics such as an Ipamorelin reference standard. Combining a GHRH analog with a Growth Hormone Secretagogue Receptor (GHSR) agonist produces a synergistic amplification of GH release without elevating plasma cortisol or prolactin levels.

Analytical Protocols: HPLC, Mass Spectrometry, and Endotoxin Standards

To guarantee experimental reproducibility, every batch of CJC-1295 No DAC produced for PX1 Research undergoes stringent third-party testing in an ISO 17025 accredited laboratory. Chemical verification relies on two primary orthogonal techniques:

1. Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC): Measures chromatographic purity by separating target peptide molecules from shorter truncation sequences or synthesis byproducts. Peak area integration must confirm a main peak area of >99.0%. 2. Electrospray Ionization Mass Spectrometry (ESI-MS): Verifies exact molecular mass to confirm that the peptide sequence corresponds precisely to the target theoretical mass of 3367.97 Da.

In addition to purity and identity confirmation, bacterial endotoxin testing via Chromogenic LAL assay is executed for every single lot. Endotoxins (lipopolysaccharides) introduce unwanted inflammatory artifacts into cell cultures and animal models, confounding cytokine and gene expression assays. PX1 Research enforces strict endotoxin limits (<0.01 EU/mg) to ensure clean bio-assays.

Reconstitution and Laboratory Handling Parameters

CJC-1295 No DAC is supplied as a lyophilized (freeze-dried) powder to maximize shelf stability during transit and storage. Reconstitution should be performed under a laminar flow hood using sterile laboratory technique.

For standard analytical or cell culture protocols, bacteriostatic water (0.9% benzyl alcohol) or sterile endotoxin-free water is introduced against the glass wall of the vial to allow gradual dissolution without violent agitation. Gentle swirling is recommended; vortexing high-concentration peptide solutions can induce mechanical shear forces that disrupt tertiary structure or lead to aggregation. Detailed protocol frameworks are accessible through the PX1 Research Literature Library.

Thermal Stability and Storage Conditions

Lyophilized CJC-1295 No DAC exhibits high stability when stored at sub-zero temperatures. Upon receipt in the laboratory, unopened vials should be stored at -20°C for short-to-medium-term stability, or -80°C for long-term storage spanning up to 24 months.

Once reconstituted, the peptide solution becomes more susceptible to thermal degradation and hydrolysis. Reconstituted vials must be kept refrigerated at 2°C to 8°C and utilized within 30 days. Repeated freeze-thaw cycles of liquid aliquots must be strictly avoided, as phase changes promote peptide precipitation and molecular breakdown.

USA Manufacturing and Lot Traceability Standards

Quality control in peptide synthesis depends heavily on process standardization and raw material purity. PX1 Research manufactures CJC-1295 No DAC within GMP-compliant, US-based synthesis facilities. Operating within domestic boundaries permits rigid adherence to American manufacturing standards, preventing batch-to-batch variability and foreign supply chain contaminants.

Every vial dispatched features full lot traceability linked directly to public COAs. Institutional buyers requiring larger quantities for multi-stage animal trials or high-throughput screens can establish supply agreements via PX1 Wholesale Lab Accounts, ensuring single-lot consistency across extended longitudinal studies.

Preclinical Research Applications in Tissue Repair Models

In academic and pharmaceutical research settings, CJC-1295 No DAC is heavily investigated for its role in cellular repair mechanisms. Because growth hormone and IGF-1 regulate protein translation, satellite cell activation, and extracellular matrix deposition, researchers utilize this GHRH analog in various preclinical models:

• Musculoskeletal Regeneration: Investigating rate of tendon, ligament, and skeletal muscle matrix turnover following mechanical stress. • Dermal Wound Healing: Evaluating collagen synthesis rates and re-epithelialization speeds in rodent lesion models. • Metabolic Regulation: Examining lipid oxidation, glucose uptake pathways, and nitrogen retention dynamics in somatopause animal models.